Cipla open to expanding manufacturing footprint to strengthen US presence | Company News

Premium

The company aims to expand this further through both organic growth and potential acquisitions. (File Image)

3 min read Last Updated : Apr 27 2025 | 1:18 PM IST

Pharmaceutical company Cipla is open to expanding its manufacturing footprint in the US, a move that can relatively de-risk the company from potential disruptions arising from evolving tariff regimes, sources said.

The US already contributes a significant share, around a quarter, of Cipla’s total revenues.

A source close to the development said that the company is “actively scaling operations in the US,” a key global market for generics, particularly in respiratory and oncology segments. 

The company currently operates with four manufacturing facilities in Massachusetts

No Byline Policy

Editorial Guidelines

Corrections Policy

Source